Apart from it, somatic mutations in the tyrosine-kinase domain of EGFR were identified in 30-50% non-small-cell lung cancers (NSCLCs) patients, among which the TKIs response rate increased to approximately 75% [55, 56]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.